Allergy Therapeutics (AGY)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 16.4 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 2.08 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 30th Jun | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | TTM | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | ||||||||||
| Operating Profit | £m | ||||||||||
| Net Profit | £m | ||||||||||
| EPS Reported | p | ||||||||||
| EPS Normalised | p | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | p | ||||||||||
| Capex ps | p | ||||||||||
| Free Cashflow ps | p | ||||||||||
| Dividends | |||||||||||
| Dividend ps | p | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | £m | ||||||||||
| Working Capital | £m | ||||||||||
| Net Fixed Assets | £m | ||||||||||
| Net Debt | £m | ||||||||||
| Book Value | £m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | p | -19.3% | |||||||||
FINANCIAL BRIEF: For the six months ended 31 December 2012, Allergy Therapeutics plc revenues decreased 10% to L25.7M. Net income decreased 42% to L4.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income also reflects Retranslation gain on Euro denominated b decrease from L966K (income) to L0K, Administration expenses - other increase of 14% to L3.6M (expense). more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Dec '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 0 | 0 | 0 | 0 | 1 |
Allergy Therapeutics Plc (AT) is engaged in the development, manufacture, marketing and sale of a range of pharmaceutical vaccine products designed for the immunological treatment of the allergic condition and also licenses in related products. Vaccinations take the form of allergen-specific, namedpatient- specific and standard products in injectable and sublingual presentations. The business is headquartered in Worthing, West Sussex, where development and manufacturing is based, with sales and marketing subsidiaries in Germany, Austria, Italy, Spain, The Netherlands, Switzerland and Argentina. The Company’s subsidiaries include Allergy Therapeutics (Holdings) Ltd, Allergy Therapeutics (UK) Ltd, Bencard Allergie GmbH, Bencard Allergie (Austria) GmbH, Allergy Therapeutics Italia s.r.l., Allergy Therapeutics Iberica S.L., Teomed A.G., Allergy Therapeutics Netherlands BV and Allergy Therapeutics Argentina S.A.
Directors: Manuel Llobet (CEO) 48, Ian Postlethwaite (Fin. Dir.) 49,
No. of Employees: 358 No. of Shareholders: n/a
| Last Annual | June 30th, 2012 |
| Last Interim | December 31st, 2012 |
| Shares in Issue | 409,866,831 |
| Free Float | 100.8m (24.6%) |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE Aim All Share, |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | Dominion Way, WORTHING, BN14 8SA, United Kingdom |
| Web | http://www.allergytherapeutics.com |
| Phone | +44 1903 844700 |
| Contact | Ian Postlethwaite (Secy.) |
| Registrar | Capita IRG plc |
| Auditors | Grant Thornton UK LLP |
| 15th May | Grant of Options |
| 25th Mar | Half Yearly Report |
| 11th Mar | Notice of results and shareholder update |
| 11th Mar | US patent granted |
| 1st Feb | Total Voting Rights |
| 22nd Jan | Exercise of Options |
Recent ↓
